skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Riviciclib (Code C64762)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Riviciclib

Definition: A flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.

Display Name: Riviciclib

Label: Riviciclib

NCI Thesaurus Code: C64762 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1832023  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Cyclin Dependent Kinase Inhibitor P276
P-276-00 Free Base

External Source Codes: 
PDQ Closed Trial Search ID 529362
PDQ Open Trial Search ID 529362 (check for NCI PDQ open clinical trial info)
UMLS CUI C1832023

Other Properties:
     Name Value (qualifiers indented underneath)
code C64762
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name P276
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom